Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Ghassan K. Abou-Alfa
Consultant or Advisory Role - Bayer
Research Funding - Amgen; Bayer
Jean-Frédéric Blanc
No relevant relationships to disclose
Steven Miles
No relevant relationships to disclose
Tom M. Ganten
No relevant relationships to disclose
Jorg Trojan
Honoraria - Amgen; Bayer
Jonathan S. Cebon
No relevant relationships to disclose
Andre K. D. Liem
No relevant relationships to disclose
Lara Rachel Lipton
No relevant relationships to disclose
Charu Gupta
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Benjamin Wu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jason B. Litten
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Other Remuneration - Amgen
Leonard Saltz
Research Funding - Amgen; Bayer